Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (2271)	11/16/2004 12:55:13 PM
From: Icebrg	Read Replies (3) of 3044

Velcade in solid tumors - part II Boronate @ Yahoo! reports from the R&D day (which webcast I have not been able to access). R&D by: boronate 11/16/04 11:26 am Msg: 56077 of 56081 Just heard the R&D day presentation on BAC, a subtype of NSCL (~20%). There are some "dramatic responses" in this subtype and Mlnm will initiate a Phase II of this trial in the 1H of 2005. Decision point on current PII Velcade or Velcade plus Taxotere by the end of this year. The SWOG frontline trial with cisplatin and gemcitabine, initiated soon after ASCO, has nearly completed its enrollment. I will expect data as early as ASCO next year. Re: R&D by: boronate 11/16/04 12:45 pm Msg: 56081 of 56081 The importance of BAC cannot be overstated. It may represent the majority of the responses seen in the current lung trials and may explain why the response rate vary so much among the small investigator-initiated trials. It is certainly a subtype that can lead to FDA approval. The new trial is a single agent trial so the response will be unmistakeble. Judging from the case presented today and a similar one shown in ASCO 2003, major responses and remission can be obtained with Velcade as a single agent. The trial can accure patients rapidly and certainly can be completed within a year from initiation. So we are looking at 2006 for an NDA. While solid tumor trials are never easy, when one sees single agent activity that falls into the major response category and a drug is apready safe in human, the bet is quite, or even extremely, good. cheers.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next